# Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer

> **NCT01936363** · PHASE2 · COMPLETED · sponsor: **EMD Serono** · enrollment: 65 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Pimasertib once daily
- **DRUG:** Pimasertib placebo
- **DRUG:** SAR245409 placebo
- **DRUG:** SAR245409
- **DRUG:** Pimasertib twice daily

## Key facts

- **NCT ID:** NCT01936363
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-30
- **Primary completion:** 2015-05-31
- **Final completion:** 2017-11-30
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2018-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01936363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01936363, "Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01936363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*